Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 20/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.62 |
| ▸ | DRD2 | P14416 | 1/20 | 0.62 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4069793 | 0.94 | CXCR4 (0.87) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| Bromide SCHEMBL5140353 | 0.93 | CXCR4 (0.86) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| SCHEMBL4073962 | 0.93 | CXCR4 (0.84) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| SCHEMBL4063485 | 0.92 | CXCR4 (0.87) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| SCHEMBL4069312 | 0.92 | CXCR4 (0.86) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| Bromide SCHEMBL5140052 | 0.92 | CXCR4 (0.86) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| SCHEMBL2511125 | 0.92 | CXCR4 (0.77) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| SCHEMBL4067896 | 0.91 | CXCR4 (0.85) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| Bromide SCHEMBL5140891 | 0.91 | CXCR4 (0.84) | CXCR4CYP2D6CHRM2DRD2OPRM1 | |
| SCHEMBL4065372 | 0.90 | CXCR4 (0.75) | CXCR4CYP2D6CHRM2DRD2OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | claimed |
| EP-1317445-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-03-11 | — | — | EP | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7396840-B2 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-7084155-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2006-08-01 | — | — | US | disclosed |
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2006-06-15 | — | — | US | disclosed |
| US-6864265-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED, INC. (CA) | 2005-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128750-A1 | Chemokine receptor binding heterocyclic compounds | CXCR4, CCR5, CXCR3 | CXCR4 1/4885CYP2D6 3062/4885CYP3A4 2593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.